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Abstract
Background: The identification of disease-related microRNAs is vital for understanding the pathogenesis of
diseases at the molecular level, and is critical for designing specific molecular tools for diagnosis, treatment and
prevention. Experimental identification of disease-related microRNAs poses considerable difficulties. Computational
analysis of microRNA-disease associations is an important complementary means for prioritizing microRNAs for
further experimental examination.
Results: Herein, we devised a computational model to infer potential microRNA-disease associations by prioritizing
the entire human microRNAome for diseases of interest. We tested the model on 270 known experimentally
verified microRNA-disease associations and achieved an area under the ROC curve of 75.80%. Moreover, we
demonstrated that the model is applicable to diseases with which no known microRNAs are associated. The
microRNAome-wide prioritization of microRNAs for 1,599 disease phenotypes is publicly released to facilitate future
identification of disease-related microRNAs.
Conclusions: We presented a network-based approach that can infer potential microRNA-disease associations and
drive testable hypotheses for the experimental efforts to identify the roles of microRNAs in human diseases.
Background
The identification of genes associated with human dis-
eases is an important goal of biomedical research.
Recently, a number of computational methods have
been developed to predict or prioritize disease-related
protein-coding genes [1-23]. Most approaches are based
on the idea that dysfunctions of functionally related pro-
tein-coding genes tend to be associated with phenotypi-
cally similar diseases [1,2,6,12,13,15,16,18-22]. These
protein-coding genes linked to similar diseases usually
interact with each other or participate in the common
biological modules. Network-based approaches have also
been employed to predict or prioritize new candidate
disease genes based upon network linkages with known
disease genes [1-3,12,23]. These approaches typically
start with constructing a gene-gene association network
based on one or more types of genomic and proteomic
information, and then prioritize candidate protein-cod-
ing genes based on network proximity to known dis-
ease-related genes. For example, Franke et al.a n d
Linghu et al. separately constructed a functional linkage
network (FLN) by integrating multiple types of data,
such as protein-protein interaction, microarray and
Gene Ontology annotation data, and utilized the FLN
for disease gene prioritization [7,23]. Lage et al. con-
structed a human phenome-interactome network and
scored each candidate protein based on the involvement
of its direct network neighbors in similar diseases [1].
The biological interpretation of a high-scoring candidate
was that the candidate was likely to be involved in the
molecular mechanism of the disorder of interest.
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important roles in the development and progression of
human diseases, and are critical for the prognosis, diag-
nosis and the evaluation of treatment responses for
these diseases [24-37]. Jiang et al. and Lu et al. indepen-
dently developed two manually curated database–miR2-
Disease [38] and Human MicroRNA Disease Database
(HMDD) [39], which aim at providing a comprehensive
resource of experimentally verified microRNA-disease
associations. However, one major issue in microRNA
studies is the lack of bioinformatics methods to infer
potential microRNA-disease associations that can guide
further biological experiments.
MicroRNAs exert their biological functions through
suppression of their target genes [40]. Accumulating
studies indicate that microRNAs usually perform related
functions by targeting either the same genes or func-
tionally related genes in a coordinated manner
[34,35,41-48]. It has become an increasingly important
and informative approach to analyze biological systems
and disease mechanisms in networks of genes and dis-
eases [6,12,21,49,50]. Establishing a functional relation-
ship between two microRNAs by their target genes and
further constructing a functionally related microRNA
network will be useful for understanding the roles of
microRNAs in diseased states.
Herein, we propose a computational approach to infer
potential microRNA-disease associations by prioritizing
the entire human microRNAome for diseases of interest.
It was a logical extension of previous network-based
method for predicting or prioritizing disease-related pro-
tein-coding genes. We first constructed a functionally
related microRNA network (Figure 1A ) and a human
phenome-microRNAome network (Figure 1B). We sub-
sequently examined whether functionally related micro-
RNAs tend to be associated with phenotypically similar
diseases and prioritized microRNAs for human diseases.
Results
Construction of human phenome-microRNAome network
In order to prioritize the entire microRNAome for dis-
eases, we constructed a functionally related microRNA
network by assuming that two microRNAs are functionally
related if the overlap between their target genes was statis-
tically significant (Figure 1A). A p-value from Fisher’s
Exact Test was used to evaluate the overlap, and was
adjusted by the Benjamini-Hochberg correction [51,52].
Two microRNAs were considered to be functionally
Figure 1 Construction and application of a human phenome-microRNAome network. (A) Construction of a functionally related microRNA
network. An edge is placed between two microRNAs if they share significant number of target genes. (B) Application of the phenome-
microRNAome network to infer new microRNA-disease associations. A gray edge connects known disease-related microRNA to the
corresponding disease. Disease 2 has a related microRNA (miR-6), and disease 4 doesn’t have any related microRNAs. The red dash lines
represent the potential microRNA-disease associations that might be predicted by this network model.
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ing this strategy, and using microRNA-target dataset pre-
dicted by Probability of Interaction by Target Accessibility
(PITA) [53], we obtained a functionally related microRNA
network that included 9,249 relationships (edges) between
514 microRNAs (nodes). We subsequently constructed a
hypothetical human phenome-microRNAome network by
integrating the microRNA network with a phenome net-
work [1,12,20] using 270 experimentally verified micro-
RNA-disease associations (Figure 1B).
Functionally related microRNAs tend to be associated
with phenotypically similar diseases
Our model was based on the notion that functionally
related microRNAs tend to be associated with phenoty-
pically similar diseases. We examined it by addressing
two questions: (1) whether disease pairs associated with
common microRNAs are phenotypically more similar,
as opposed to randomly selected phenotype pairs; and
(2) whether the microRNA pairs associated with com-
mon diseases are functionally more related. Because we
have constructed a functionally related microRNA net-
work, the functional relatedness between two micro-
RNAs can be measured through the number of shared
network neighbors and the length of the shortest path
in the microRNA network. We chose to use these two
measures mainly based on the standpoint that, in a
functional network, if two nodes are less distant from
each other or share more neighbors, they are function-
ally more related. Herein, we used the function e
-x to
convert the length of the shortest path to the degree of
functional relatedness between two microRNAs.
A total of 349 disease pairs were identified to be asso-
ciated with common microRNAs, and 1,252 microRNA
pairs were found to be associated with common diseases.
To evaluate the statistical significance of the phenotypic
similarity between diseases associated with common
microRNAs, we generated 10,000 negative control sets and
calculated an average phenotypic similarity score for each
set containing 349 disease pairs that were randomly
sampled from the human phenome. The average phenoty-
pic similarity score between diseases associated with com-
mon microRNAs was significantly higher than the
similarity of randomly selected phenotype pairs from the
human phenome (p <1 0
-4, Figure 2A). In a similar man-
ner, we generated another 10,000 negative control sets and
calculated the average functional relatedness for each set
containing 1,252 microRNA pairs randomly sampled from
the microRNA network. The microRNA pairs associated
with common diseases shared more common network
neighbors (p <1 0
-4, Figure 2B), and were less distant from
each other in the microRNA network (p <1 0
-4, Figure 2C).
Performance evaluation
In order to assess the power of our model to infer
microRNA-disease associations by prioritizing the entire
Figure 2 Functionally related microRNAs tend to be associated with Phenotypically similar diseases. (A) The observed average
phenotypic similarity score (arrow) of 349 phenotype pairs associated with common microRNAs and the distribution of expected average
phenotypic similarity scores (curve) of 10,000 random control sets containing the same number of randomly sampled phenotype pairs (p<10
-4).
(B, C) The observed average functional relatedness (arrow) of 1,252 microRNA pairs associated with common diseases and the distribution of the
expected average functional relatedness (curve) of 10,000 random control sets containing the same number of randomly sampled microRNA
pairs (p<10
-4). The measures for functional relatedness between microRNAs are the average number of shared network neighbors and a function
value that is derived from the shortest path length.
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validation on 270 known experimentally verified micro-
RNA-disease associations. Each association was left out
once as the testing case, being referred to as <m, d>.
For the disease d,t h em i c r o R N Am was termed ‘defec-
tor’ microRNA. We prioritized the entire microRNAome
according to the scores derived from the scoring system.
Note that the score can be computed only for all micro-
RNAs in the microRNA network, which was termed the
ranked microRNAome. If the ranking of the ‘defector’
microRNA exceeds a given threshold, the model suc-
cessfully predicts the experimentally verified association
<m, d>.
We calculated the sensitivity and specificity for each
threshold. Sensitivity refers to the percentage of the
‘defector’ m i c r o R N A sw h o s er a n k i n gi sh i g h e rt h a na
given threshold, namely the ratio of the successfully
predicted experimentally verified microRNA-disease asso-
ciations to the total experimentally verified microRNA-
disease associations. Specificity refers to the percentage
of microRNAs that are below the threshold. The same
computational strategies were applied by Endeavour [13]
and GeneWanderer [2]. A receiver-operating characteris-
tics (ROC) curve was plotted by varying the threshold,
and the standard area under curve (AUC) was calculated.
When our model was tested on 270 experimentally veri-
fied microRNA-disease associations, an AUC of 75.80%
was achieved (red curve in Figure 3), suggesting that our
model can recover the known experimentally verified
microRNA-disease associations, and therefore has the
Figure 3 Leave-one-out cross-validation results. The red curve was derived from 270 experimentally verified microRNA-disease associations.
The blue curve represents the performance of the model to prioritize microRNAs for diseases with which no microRNAs have been
experimentally verified to be associated. The green curve was obtained from 270 randomly generated microRNA-disease associations.
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prioritizing the microRNAome.
In order to ensure that the prioritization represents
biological significance, the model was tested on the 270
randomly generated microRNA-disease associations,
which resulted in an AUC of 49.81% (green curve in
Figure 3), approximate to the uninformative AUC of
50% (dash line in Figure 3). This result showed indir-
ectly that our model can obtain a biologically meaning-
ful prioritization.
Applicability of the model to diseases without any
known related microRNAs
To demonstrate that our model is applicable to the dis-
eases without any known related microRNAs, we
removed all other experimentally verified microRNA-
disease associations that are involved in the disease d,
for each of the 270 known experimentally verified
microRNA-disease associations, denoted as <m, d>.
This step ensured that prioritizing microRNAs for the
disease d only took advantage of the information of
other diseases having similar phenotypes with the dis-
ease d. When our model was tested on this dataset, an
AUC of 69.51% was obtained (blue curve in Figure 3),
suggesting that the model had the potential to achieve
the goal of predicting potential microRNA-disease asso-
ciations for the diseases without any known related
microRNAs.
Effect of microRNA families and robustness
MicroRNAs belonging to the same family have similar
target profiles because they share the “seed” region close
to the 5’ end of the microRNAs, which is the main
determinant of microRNA targeting. One possible con-
cern is the potential confounding effect of microRNA
families in the performance evaluation procedure. If sev-
eral microRNAs (mi, i=1, 2…) belonging to the same
family are associated with a certain disease d,i tm i g h t
be relatively easy for the leave-one-out cross-validation
procedure to recover the experimentally verified micro-
RNA-disease association <mi, d> being examined. To
assess the possible effect of this confounding factor, we
removed all other experimentally verified associations
between the disease d and microRNAs which belong to
the same family as the microRNA m. Following this pro-
cedure, a slightly reduced AUC of 71.39% was achieved
(black curve in Figure 3), suggesting that microRNA
families are not a main factor leading to the good per-
formance of our model.
There is great difference among the microRNA-target
lists predicted by different algorithms. Herein, we exam-
ined the robustness of our model to another micro-
RNA-target list predicted by TargetScan [54], one of the
leading target prediction tools. We constructed another
functionally related microRNA network by retrieving the
15,000 most significant microRNA-microRNA relation-
ships (edges) between 541 microRNAs (nodes). Based
on this microRNA network, we created another phe-
nome-microRNAome network and obtained a compar-
a b l ep e r f o r m a n c eb yt e s t i n gt h em o d e lo nt h e2 7 0
known microRNA-disease associations, indicating that
our model isn’t limited to a specific target prediction
algorithm.
Prioritizing the entire microRNAome for 1,599 disease
phenotypes
Many disease microRNAs have been identified over the
past decade. However, the majority of diseases in the
OMIM database aren’t associated with any microRNA.
One reason is that no sufficient efforts have been made
to decipher potential roles of microRNAs in those dis-
eases. To provide testable hypotheses to guide future
experiments, it is important to computationally infer
possible microRNA-disease associations for diseases of
interest.
Two disease phenotypes were defined to be similar if
they have a phenotypic similarity score no less than 0.3
[19]. We thus obtained 1,599 disease phenotypes, which
are similar to at least one of the disease phenotypes in
the benchmark dataset (see Additional file 1). We priori-
tized the entire microRNAome for 1,599 disease pheno-
types according to score derived from the scoring system.
In addition, the top 100 microRNAs for each of the 1,599
phenotypes are publicly released to facilitate the discov-
ery of disease microRNAs (see Additional file 2).
Case study: breast cancer
We presented a case study for breast cancer, which is
one of the most commonly occurring cancers among
women and accounts for 22% of all female cancers. We
prioritized all microRNAs for breast cancer. Among the
top 100 microRNAs, 17 have been confirmed to contri-
bute to the development of breast cancer, and 13 were
verified to be deregulated in breast cancer cells. By lit-
erature retrieval, we provided more supporting evidence
in Additional file 3. For example, Reddy et al.f o u n d
that miR-7 inhibits p21-activated kinase 1 (Pak1) expres-
sion, a widely up-regulated signaling kinase in multiple
human cancers, and the miR-7 introduction inhibits the
motility, invasiveness, anchorage-independent growth
and tumorigenic potential of highly invasive breast can-
cer cells [55]. Foekens et al. also linked miR-7 to breast
cancer aggressiveness [56]. In addition, Scott et al.
found that miR-125b is down-regulated in breast cancer
and miR-125a or miR-125b-overexpressing SKBR3 cells
displayed diminished plating and anchorage-dependent
growth in addition to markedly reduced cell migration
and invasion capacities.
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We demonstrated that the method we proposed achieved
good performance in recovering known, experimentally
verified microRNA-disease associations. Using the model,
we prioritized the entire microRNAome for 1,599 dis-
eases, most of which have not been linked to any micro-
RNAs. The power of our model can be attributed to
several factors. First, we constructed a functionally
related microRNA network, which can capture the biolo-
gical characteristics of some microRNAs that tend to
exert the same or similar functions by the inhibition of
common target genes in a coordinated manner. Second,
we took full advantage of large-scale phenotype similarity
score information, whose significance has been con-
firmed in several previous studies aiming at the identifi-
cation of disease-related protein-coding genes [1,12].
Third, we used experimentally verified microRNA-dis-
ease associations, which allow connecting the human dis-
ease network with the microRNA network, and therefore
provide underlying knowledge for the role of microRNA
in disease pathogenesis.
There are several potential limitations. First, the
known experimentally verified microRNA-disease asso-
ciations were insufficient. Second, the functionally
related microRNA network was constructed based on
the standpoint that two microRNAs are functionally
related if the number of share dt a r g e tg e n e si ss t a t i s t i -
cally significant. In reality, two microRNAs may be
functionally related when their target genes reside in
the same cellular pathways or functional modules
[43,57], rather than overlap significantly. Therefore,
integrating other bioinformatics sources such as Gene
Ontology annotation and protein-protein interaction
network data might improve model performance. In
addition, modeling rules connecting phenotype with
microRNA network may represent an important step on
the path of the emerging field of “network medicine”
[21,58].
Conclusions
Evidence continually reinforces the notion that function-
ally related protein-coding genes are usually associated
Figure 4 Steps in prioritizing the entire microRNAome for a disease of interest. First, a virtual pull-down of each candidate generates a
hypothetical microRNA module, defined as a given microRNA (the center of the module) plus its direct network neighbors in the functionally
related microRNA network. Second, in each microRNA module, the microRNAs linked to diseases that have similar phenotypes with the disease
being investigated are identified. Finally, all candidates are scored and prioritized.
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notion, many innovative methodologies have been pro-
posed to predict or prioritize protein-coding genes for
complex diseases [1-3,7,11,12]. In this study, we studied
the functional correlation of microRNAs and found that
disease pairs associated with common microRNAs were
phenotypically more similar, and the microRNA pairs
linked to common diseases were functionally more
related. We further constructed an integrated phenome-
microRNAome network, through which we devised a
method that can recover the known experimentally veri-
fied microRNA-disease associations and prioritize the
entire microRNAome for 1,599 diseases. The top 100
microRNAs for each of the 1,599 diseases are released
publicly, which will provide testable hypotheses to guide
further experiments and contribute to the identification
of true disease-related microRNAs.
Methods
Data sources
We downloaded the disease phenotype similarity scores
from the MimMiner [19], developed by Driel et al. who
computed a phenotype similarity score for each pheno-
type pair by the text mining analysis of their phenotype
descriptions in the Online Mendelian Inheritance in
Man (OMIM) database [59]. The disease phenotype net-
work was constructed based on the similarity score.
Two phenotypes were considered to be similar and were
linked by an edge if their similarity score was no less
than 0.3. The similarity score is equal to 1 if two pheno-
types are identical. The phenotypic similarity score has
been successfully used to predict or prioritize disease-
related protein-coding genes [3,12].
PITA [53] is a leading microRNA target prediction
approach that considers multiple factors, such as seed
pairing, site number, overall predicted pairing stability
and predicted site accessibility. We downloaded the
PITA target catalog version 6 (3/15 flank ALL 31-Aug-
08) and retrieved 145,872 predicted associations between
670 microRNAs and 14,826 target genes with a score
less than -10.0, a threshold suggested by PITA, In addi-
tion, we downloaded 205,587 associations between 675
microRNAs and 11,758 target genes predicted by Tar-
getScan (version5.1, conserved sites) [54], another lead-
ing target prediction algorithm.
miR2Disease [38] and HMDD [39] databases provide
comprehensive resources for microRNA deregulation in
human disease. From these databases, we selected 270
high-quality experimentally verified microRNA-disease
associations that microRNA deregulation has been
experimentally verified to contribute to the disease
development. For instance, Ma et al.r e p o r t e dt h a t
highly expressed miR-10b initiates tumor invasion and
metastasis in breast cancer through translational
inhibition of HOXD10, and eventually increases expres-
sion of RHOC, a pro-metastatic gene [60]. The 270
associations (see Additional file 1) were used as the
benchmark dataset for the performance evaluation of
our model.
microRNA family dataset was retrieved from miRBase
database [61].
Computational model
Based on the idea that functionally related microRNAs
tend to be associated with phenotypically similar dis-
eases, we developed a scoring system to assess how
likely a microRNA may be involved in a specific disease
phenotype. For a given disease d,am i c r o R N Am a yb e
related if it and its direct network neighbors in the
microRNA network contain microRNAs having been
linked to the phenotypically similar diseases. All micro-
RNAs were prioritized according to score. The top-
ranked microRNAs can be expected to have a high
probability of representing bona fide disease micro-
RNAs, which will generate testable hypotheses to guide
the future experiments and may significantly reduce the
cost and effort to identify the bona fide disease micro-
RNAs. The key steps are illustrated in Figure 4.
Scoring system
The hypergeometric distribution is a discrete probability
distribution that describes the number of successes in a
sequence of n draws from a finite population without
replacement. For example, there is a shipment of N
objects in which M are defective. The hypergeometric
distribution describes the probability that exactly m
objects are defective in a sample of n distinct objects
drawn from the shipment.
Herein, for a disease d of interest, each microRNA in
the microRNA network is scored through the cumula-
tive hypergeometric distribution:
score i
M
ni
NM
n
N
im
M
=− −
−
= ∑ 1
() ( )
()
(1)
The biological interpretation of a high-scoring micro-
R N Ai st h a ti ti sl i k e l yt ob ei n v o l v e di nt h ed i s e a s ed.
Here, N is the total number of microRNAs in the whole
functionally related microRNA network. M is the num-
ber of microRNAs in the whole microRNA network
associated with diseases that are similar to the disease d.
n denotes the number of microRNAs in the correspond-
ing microRNA module. A module is defined as a given
microRNA (the center of the module) plus its direct
network neighbors. m is the number of microRNAs that
are associated with similar diseases and are found in the
corresponding module.
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Page 7 of 9Additional file 1: 270 experimentally verified microRNA-disease
associations.Each line represents an association between a microRNA
and a disease.
Additional file 2: 100 top-ranked microRNAs for each of 1,599
diseases.Each line represents a potential association between microRNA
and disease, including MIM ID, microRNA ID and score.
Additional file 3: Literature evidence to support the top 100
microRNAs for breast cancer.
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